Register for alerts
If you have registered for alerts, you should use your registered email address as your username
Ten new studies were identified so a total of 34 studies (3033 total participants) were included in the 2015 review update. The risk of bias attributes were frequently poorly performed. Low risk of bias was reported in 18 studies for sequence generation, 16 studies for allocation concealment , seven for performance and detection bias , 15 for incomplete reporting and 16 for selective reporting. Three months or more of prednisone significantly reduced the risk of frequently relapsing nephrotic syndrome (FRNS) (6 studies, 582 children: RR , 95% CI to ) and of relapse by 12 to 24 months (8 studies, 741 children: RR , 95% CI to ) compared with two months. Five or six months of prednisone significantly reduced the risk of relapse (7 studies, 763 children: RR , 95% CI to ) but not FRNS (5 studies, 591 children: RR , 95% CI to ) compared with three months. However there was significant heterogeneity in the analyses. Subgroup analysis stratified by risk of bias for allocation concealment showed that the risk for FRNS did not differ significantly between two or three months of prednisone and three to six months among studies at low risk of bias but was significantly reduced in extended duration studies compared with two or three months in studies at high risk or unclear risk of bias . There were no significant differences in the risk of adverse effects between extended duration and two or three months of prednisone. Four studies found that in children with FRNS, daily prednisone during viral infections compared with alternate-day prednisone or no treatment significantly reduced the rate of relapse .